Merus (NASDAQ:MRUS – Get Free Report) VP Harry Shuman sold 7,300 shares of Merus stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $57.84, for a total value of $422,232.00. Following the completion of the transaction, the vice president now directly owns 7,002 shares in the company, […]
Avoro Capital Advisors LLC increased its stake in Merus (NASDAQ:MRUS – Free Report) by 100.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 888,888 shares of the biotechnology company’s stock after purchasing an additional 444,444 shares during the quarter. Avoro Capital Advisors LLC’s holdings in Merus were worth $24,444,000 as of its most […]
Carmignac Gestion reduced its position in Merus (NASDAQ:MRUS – Free Report) by 11.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 403,861 shares of the biotechnology company’s stock after selling 50,470 shares during the period. Carmignac Gestion owned approximately 0.70% […]
Merus (NASDAQ:MRUS – Free Report) had its price target lifted by Stifel Nicolaus from $65.00 to $90.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other research firms also recently issued reports on MRUS. StockNews.com downgraded shares of […]
Merus (NASDAQ:MRUS – Free Report) had its target price lifted by Guggenheim from $57.00 to $93.00 in a research note published on Tuesday, Benzinga reports. Guggenheim currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently weighed in on MRUS. Stifel Nicolaus increased their price target on shares of […]